Liu Zhenggang, Guo Mengnan, Li Yumei, Xu Hui
Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Front Med (Lausanne). 2025 Apr 17;12:1554669. doi: 10.3389/fmed.2025.1554669. eCollection 2025.
Atopic dermatitis (AD) is a chronic inflammatory skin condition with a high prevalence worldwide and multifaceted pathogenesis. In general, patients with moderate to severe AD often experience relapse after discontinuing treatment. Therefore, to understand the possible factors of chronic relapse of AD and to look for biological markers that predict the relapse or poor prognosis of AD will be helpful for clinical treatment. Mutations in genes such as FLG, SPINK5, STAT, KIF3A, claudin-1, Ovol1, and HLA-DRB1 offer new insights into the genetic basis of AD. Routine factors may help improve patient lifestyle, highlight the importance of environmental influences (including psychological stress), and support clinicians in optimizing anti-infective treatment strategies. The inflammatory axis (CD30-CD30L axis, IL-9-IL-18 axis) provides new insights into the inflammatory pathways of AD and may be a target for future therapies. Low NKG2D expression may have adverse effects on prognosis. Prognostic biomarkers can play an important role in treatment monitoring, disease progression and recurrence, and provide the possibility for more personalized treatment.
特应性皮炎(AD)是一种慢性炎症性皮肤病,在全球范围内患病率很高,发病机制具有多方面特点。一般来说,中重度AD患者在停止治疗后常出现复发。因此,了解AD慢性复发的可能因素并寻找预测AD复发或预后不良的生物标志物将有助于临床治疗。FLG、SPINK5、STAT、KIF3A、claudin-1、Ovol1和HLA-DRB1等基因的突变为AD的遗传基础提供了新的见解。常规因素可能有助于改善患者生活方式,突出环境影响(包括心理压力)的重要性,并支持临床医生优化抗感染治疗策略。炎症轴(CD30-CD30L轴、IL-9-IL-18轴)为AD的炎症途径提供了新的见解,可能成为未来治疗的靶点。低NKG2D表达可能对预后产生不利影响。预后生物标志物可在治疗监测、疾病进展和复发中发挥重要作用,并为更个性化的治疗提供可能。